Literature DB >> 15942100

High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement.

Yasuhiro Shimojima1, Masayuki Matsuda, Wataru Ishii, Jun Koyama, Kanji Yamamoto, Shigetaka Shimodaira, Kazuo Sakashita, Kenichi Koike, Shu-ichi Ikeda.   

Abstract

A patient with primary systemic AL amyloidosis achieved partial hematological response after 2 courses of VAD (vincristine, doxorubicin and dexamethasone) and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation despite involvement of multiple organs, including the heart. In this patient natriuretic peptides and free light chains in serum were useful as markers of cardiac involvement and therapeutic effects, respectively. When amyloidosis-related dysfunction is seen in multiple organs, this intensive chemotherapy might be a possible therapeutic option, although several modifications in the regimen and careful management are necessary.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942100     DOI: 10.2169/internalmedicine.44.484

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis.

Authors:  Junichi Hoshino; Yoshifumi Ubara; Naoki Sawa; Keiichi Sumida; Rikako Hiramatsu; Eiko Hasegawa; Tatsuya Suwabe; Noriko Hayami; Masayuki Yamanouchi; Fumi Takemoto; Shuichi Taniguchi; Kenmei Takaichi
Journal:  Clin Exp Nephrol       Date:  2011-03-09       Impact factor: 2.801

2.  Primary localized amyloidosis causing urethral stricture disease: a mimicker of urothelial carcinoma.

Authors:  Jas Singh
Journal:  J Surg Case Rep       Date:  2021-05-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.